Management of Intrahepatic Cholestasis of Pregnancy: Recommendations of the Working Group on Obstetrics and Prenatal Medicine - Section on Maternal Disorders

Hagenbeck C, Hamza A, Kehl S, Maul H, Lammert F, Keitel V, Hutten MC, Pecks U (2021)


Publication Type: Journal article

Publication year: 2021

Journal

Book Volume: 81

Pages Range: 922-939

Journal Issue: 8

DOI: 10.1055/a-1386-3912

Abstract

Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disease specific to pregnancy. The cardinal symptom of pruritus and a concomitant elevated level of bile acids in the serum and/or alanine aminotransferase (ALT) are suggestive for the diagnosis. Overall, the maternal prognosis is good. The fetal outcome depends on the bile acid level. ICP is associated with increased risks for adverse perinatal outcomes, including preterm delivery, meconium-stained amniotic fluid, and stillbirth. Acute fetal asphyxia and not chronic uteroplacental dysfunction leads to stillbirth. Therefore, predictive fetal monitoring is not possible. While medication with ursodeoxycholic acid (UDCA) improves pruritus, it has not been shown to affect fetal outcome. The indication for induction of labour depends on bile acid levels and gestational age. There is a high risk of recurrence in subsequent pregnancies.

Authors with CRIS profile

Involved external institutions

How to cite

APA:

Hagenbeck, C., Hamza, A., Kehl, S., Maul, H., Lammert, F., Keitel, V.,... Pecks, U. (2021). Management of Intrahepatic Cholestasis of Pregnancy: Recommendations of the Working Group on Obstetrics and Prenatal Medicine - Section on Maternal Disorders. Geburtshilfe und Frauenheilkunde, 81(8), 922-939. https://doi.org/10.1055/a-1386-3912

MLA:

Hagenbeck, Carsten, et al. "Management of Intrahepatic Cholestasis of Pregnancy: Recommendations of the Working Group on Obstetrics and Prenatal Medicine - Section on Maternal Disorders." Geburtshilfe und Frauenheilkunde 81.8 (2021): 922-939.

BibTeX: Download